Biodexa Pharmaceuticals (BDRX) Cash from Financing Activities (2015 - 2022)
Biodexa Pharmaceuticals (BDRX) reported Cash from Financing Activities of -$91488.4 for Q4 2022, up 16.21% on a YoY basis from -$78726.2 in Q4 2021, and up 5.16% sequentially from -$96464.6 in Q3 2022.
Biodexa Pharmaceuticals (BDRX) Cash from Financing Activities (2015 - 2022) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 7 years of Cash from Financing Activities data on file, last reported at -$91488.4 in Q4 2022.
- For the quarter ending Q4 2022, Cash from Financing Activities rose 16.21% year-over-year to -$91488.4; the trailing twelve-month figure through Dec 2022 stood at -$409690.2 (down 153.11% YoY), and the FY2025 full-year result was $17.2 million, up 56.53% from the prior year.
- Cash from Financing Activities improved to -$91488.4 in Q4 2022, from -$96464.6 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $15.7 million in Q4 2019 to a low of -$112548.3 in Q3 2021.
- A 5-year average of $2.0 million and a median of -$50247.9 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 174729.86% in 2019 and tumbled 123.21% in 2021, its largest moves.
- Tracing BDRX's Cash from Financing Activities over 5 years: stood at -$9007.4 in 2018, then jumped by 174729.86% to $15.7 million in 2019, then plunged by 96.77% to $508373.6 in 2020, then plunged by 121.48% to -$109188.9 in 2021, then grew by 16.21% to -$91488.4 in 2022.
- Business Quant data shows BDRX's Cash from Financing Activities at -$91488.4 in Q4 2022, -$96464.6 in Q3 2022, and -$109188.9 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -91,488.41 |
| Dec 31, 2022 | -91,488.41 |
| Sep 14, 2022 | -96,464.63 |
| Sep 14, 2022 | -96,464.63 |
| Dec 31, 2021 | -109,188.86 |
| Dec 31, 2021 | -109,188.86 |
| Sep 17, 2021 | -112,548.28 |
| Sep 17, 2021 | -112,548.28 |
| Dec 31, 2020 | 508,373.64 |
| Dec 31, 2020 | 508,373.64 |
| Sep 10, 2020 | 484,822.94 |
| Sep 10, 2020 | 484,822.94 |
| Dec 31, 2019 | 15.73 Mn |
| Dec 31, 2019 | 15.73 Mn |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2015 | -332,330.43 |
| Dec 31, 2015 | -332,330.43 |